[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370343-105":59,"doc-detail-370343-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-arachidonic-acid-metabolism-enhances-immunotherapy-efficacy-in-arid1a-deficient-colorectal-cancer","Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer","","AT-rich interactive domain-containing protein 1A (ARID1A) is mutated in about 10% of colorectal cancers and its loss associates with heightened immune activity, yet immune checkpoint inhibitors remain limited in efficacy. This study shows that arachidonic acid metabolism inhibitors synergize with ICIs in ARID1A-deficient colorectal cancer by boosting CD8+ T-cell activity and suppressing vasculogenic mimicry. ATAC-seq and ChIP–qPCR indicate ARID1A deficiency reduces PTGS1/PTGS2, creating dependence on residual AA pathway function, and aspirin selectively inhibits tumor growth while sensitizing to immunotherapy, suggesting a therapeutic strategy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-arachidonic-acid-metabolism-enhances-immunotherapy-efficacy-in-arid1a-deficient-colorectal-cancer/370343/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-arachidonic-acid-metabolism-enhances-immunotherapy-efficacy-in-arid1a-deficient-colorectal-cancer/370343.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the role of ARID1A in colorectal cancer?","Question",{"text":112,"@type":113},"ARID1A is mutated in approximately 10% of colorectal cancers and ARID1A deficiency is associated with increased immune activity, including CD8+ T-cell infiltration.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do AA metabolism inhibitors work with immune checkpoint inhibitors in ARID1A-deficient tumors?",{"text":117,"@type":113},"They synergize with ICIs by enhancing CD8+ T-cell activity and inhibiting vasculogenic mimicry, improving antitumor immune responses.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is aspirin relevant to AA pathway targeting in this study?",{"text":121,"@type":113},"The study shows ARID1A loss reduces PTGS1 and PTGS2, making ARID1A-deficient cells rely on remaining AA pathway function; aspirin selectively suppresses growth and sensitizes tumors to immunotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370343,1790216221,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer  \nLuying Cui1,2,3, Ruiqi Liu4, Shuling Han1,2,3, Chunhui Zhang1, Bojun Wang1,2,3, Yuli Ruan1,2,3, Xuefan Yu1,2,3, Yien Li5, Yuanfei Yao1,2,3, Xin Guan1,2,3, Yuanyu Liao1,2,3, Dan Su1,2,3, Yue Ma1,2,3, Shuijie Li6,7, Chao Liu1,2,3, and Yanqiao Zhang1,2,3  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | AT-rich interactive domain-containing protein 1A (ARID1A), a core constituent of the switch/sucrose nonfermentable (SWI/ SNF) complex, is mutated in approximately 10% of colorectal cancers. Whereas ARID1A deficiency corresponds to heightened immune activity in colorectal cancer, immune checkpoint inhibitors (ICI) have shown limited efficacy in these tumors. The discovery of targetable vulnerabilities associated with ARID1A deficiency in colorectal cancer could expand treatment options for patients. In this study, we demonstrated that arachidonic acid (AA) metabolism inhibitors synergize with ICIs in ARID1A-deficient colorectal cancer by enhancing the activity of CD8+ T cells and inhibiting vasculogenic mimicry. Epigenetic analysis using ATAC-seq and ChIP–qPCR revealed that the lack of ARID1A results in reduced levels of PTGS1 and PTGS2, the key enzymes that control the AA pathway. Low PTGS1 and PTGS2 expression generated a reliance on the remaining functionality of the AA pathway in ARID1A-deficient cells. The AA pathway inhibitor aspirin selectively inhibited the growth of ARID1A-deficient colorectal cancer, and aspirin sensitized tumors lacking ARID1A to immunotherapy. Together, these findings suggest that blocking AA metabolism can enhance immune responses against tumors by activating CD8+ T cells and inhibiting vasculogenic mimicry, which synergizes with ICIs to improve treatment of ARID1Adeficient colorectal cancer. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Significance: The arachidonic acid pathway is a metabolic vulnerability in ARID1A-deficient colorectal cancer that can be targeted with aspirin to suppress tumor growth and enhance sensitivity to immunotherapy, providing a promising therapeutic strategy.\u003Cbr>|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\n􀀶  \nIntroduction  \nAT-rich interactive domain-containing protein 1A (ARID1A) is responsible for encoding a switch/sucrose nonfermentable (SWI/SNF) complex and mutated in approximately 10% of colorectal cancers (1, 2). Increasing evidence suggests that ARID1A deficiency impairs the interaction with MSH2 and was positively correlated with the  \n1Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. 2Key Laboratory of Tumor Immunology in Heilongjiang, Harbin, China. 3Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin, China. 4Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. 5Department of Colorectal Su","cbCaiidlLxRBUzUL","https://ap.wps.com/l/cbCaiidlLxRBUzUL","pdf",36254825,17,"English","# Introduction\n## ARID1A mutation and immune activity in colorectal cancer\n## Rationale for targeting arachidonic acid metabolism\n## Study objective and approach","[{\"question\":\"What is the role of ARID1A in colorectal cancer?\",\"answer\":\"ARID1A is mutated in approximately 10% of colorectal cancers and ARID1A deficiency is associated with increased immune activity, including CD8+ T-cell infiltration.\"},{\"question\":\"How do AA metabolism inhibitors work with immune checkpoint inhibitors in ARID1A-deficient tumors?\",\"answer\":\"They synergize with ICIs by enhancing CD8+ T-cell activity and inhibiting vasculogenic mimicry, improving antitumor immune responses.\"},{\"question\":\"Why is aspirin relevant to AA pathway targeting in this study?\",\"answer\":\"The study shows ARID1A loss reduces PTGS1 and PTGS2, making ARID1A-deficient cells rely on remaining AA pathway function; aspirin selectively suppresses growth and sensitizes tumors to immunotherapy.\"}]","Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer | PDF",1790188132,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1186bab8d747f80acf54730849970ac0.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cbc404c59ae487ea3909e079a0ff2cb.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e05f79b6a615b4ffe8a5e9e25fc4641.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d15ddcee46587bce0785cc0af4cff33.webp",980,1311]